{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:00:55Z","timestamp":1791687655411,"version":"4.3.4"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T00:00:00Z","timestamp":1428537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:p>Personalized health care (PHC) is an evolving field of medicine aimed at providing the right therapy to the right patient at the right time. This approach often incorporates the use of companion diagnostics (CDx) assays that provide information essential for the safe and effective use of the corresponding drug. In addition to oncology, many other therapy areas, such as cardiovascular, neurological, and infectious and inflammatory diseases, may benefit from PHC, owing to disease complexity and heterogeneity. Furthermore, although most U.S. Food and Drug Administration\u2013approved CDx are based on molecular\u2010based technologies, immunoassays can provide a significant contribution to the evolution of CDx in patient management. In this review we discuss how the incorporation of biomarker immunoassays into routine diagnostic testing may allow early and definitive detection of Alzheimer's disease and enable population enrichment in clinical trials. In addition, we will describe how biomarker\u2010based CDx immunoassays have potential utility for stratifying patients with asthma based on their potential response to therapy and for selecting treatment according to phenotypic profile. Continued research into the underlying disease pathology and development of accurate and reliable diagnostic assays may ensure that PHC becomes the future standard for many indications.<\/jats:p>","DOI":"10.1111\/nyas.12754","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T17:20:06Z","timestamp":1428600006000},"page":"71-80","source":"Crossref","is-referenced-by-count":18,"title":["Personalized health care beyond oncology: new indications for immunoassay\u2010based companion diagnostics"],"prefix":"10.1111","volume":"1346","author":[{"given":"Richard","family":"Batrla","sequence":"first","affiliation":[{"name":"Roche Diagnostics International Ltd  Rotkreuz Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.M.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Roche Diagnostics International Ltd  Rotkreuz Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-179"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-012-1188-9"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S15081"},{"key":"e_1_2_8_5_1","article-title":"Guidance for industry","author":"U.S. Department of Health and Human Services Food and Drug Administration","year":"2013","journal-title":"Bioanalytical method validation"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00078"},{"key":"e_1_2_8_7_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration.2014.In vitro companion diagnostic devices. Guidance for industry and Food and Drug Administration staff. August 6 2014. Cited November 4 2014.http:\/\/www.stfda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM262327.pdf."},{"key":"e_1_2_8_8_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration.2014.List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Cited November 4 2014.http:\/\/www.fda.gov\/MedicalDevices\/ProductsandMedicalProcedures\/InVitroDiagnostics\/ucm301431.htm."},{"key":"e_1_2_8_9_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration.2014.Table of pharmacogenomic biomarkers in drug labeling. Cited November 4 2014.http:\/\/www.fda.gov\/drugs\/scienceresearch\/researchareas\/pharmacogenetics\/ucm083378.htm."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00141"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2014.00438"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i1.21"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/260348"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1313943"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006221"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e3283413105"},{"key":"e_1_2_8_18_1","first-page":"500","article-title":"CFTR modulators for the treatment of cystic fibrosis","volume":"39","author":"Pettit R.S.","year":"2014","journal-title":"P T."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.06.006"},{"key":"e_1_2_8_20_1","unstructured":"National Institute for Health and Care Excellence.2013.Diagnosis and management of chronic hepatitis B in children young people and adults. NICE clinical guideline 165. June 2013. Cited November 4 2014.http:\/\/www.nice.org.uk\/guidance\/cg165\/resources\/guidance\u2010hepatitis\u2010b\u2010chronic\u2010pdf."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.02.004"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-014-0195-1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.12.58"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2243"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-72"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3115"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.05.1689"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70090-0"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.3.noc60123"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2008.596"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70291-0"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.11.003"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.01.010"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03694.x"},{"key":"e_1_2_8_35_1","unstructured":"Global Initiative for Asthma.2014.Global strategy for asthma management and prevention 2014. Cited November 4 2014.http:\/\/www.ginasthma.org\/local\/uploads\/files\/GINA_Report_2014_Aug12.pdf."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0741"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00120714"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69290-8"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.03.008"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.13-RAI-0678"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.02.046"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000028"},{"key":"e_1_2_8_43_1","unstructured":"National Heart Lung and Blood Institute.2007.Guidelines for the diagnosis and management of asthma. Full Report. August 28 2007. Cited November 4 2014.http:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/asthgdln.pdf."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.06.025"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106469"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.12.1064"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2008.15"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002359"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0392OC"},{"key":"e_1_2_8_50_1","first-page":"S25","article-title":"The Elecsys Periostin assay as a companion diagnostic for the novel asthma drug lebrikizumab","volume":"60","author":"Sherman J.","year":"2014","journal-title":"Clin. Chem."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201208-1414OC"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.13-RA-0670"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnyas.12754","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.12754","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/nyas.12754","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.12754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T20:45:44Z","timestamp":1696193144000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.12754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,9]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/nyas.12754"],"URL":"https:\/\/doi.org\/10.1111\/nyas.12754","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,9]]}}}